The results of the in vivo experiment confirmed that CSP therapy ameliorates liver inflammation by inhibiting both the mRNA and protein levels of inflammatory factors, including TNFα, IL-1β, IL-6, and iNOS in the livers of mice with NAFLD. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatotic liver disease.